U.S., June 19 -- ClinicalTrials.gov registry received information related to the study (NCT07027163) titled 'A Study About the Use of Omalizumab in the Treatment of Food Allergy and Anaphylaxis' on June 10.
Brief Summary: This was a retrospective, multi-center observational study conducted across four allergy departments in Europe (Berlin, Leipzig, Barcelona, and Basel). The study included patients with immunoglobulin E (IgE)-mediated food allergy who were treated with omalizumab, either as monotherapy or in combination with oral immunotherapy (OIT) between 2002-2022.
Study Start Date: June 01, 2023
Study Type: OBSERVATIONAL
Condition:
Food Hypersensitivity
Anaphylaxis
Recruitment Status: COMPLETED
Sponsor: Novartis Pharmaceuticals
...